BTOG 2017 | PD-L1 testing in first-line treatment of NSCLC
In this interview, Benjamin Besse, MD, PhD, Institut Gustave Roussy, Paris, France, addresses challenges associated with PD-L1 testing, and advocates for reflex PD-L1 testing at the time of diagnosis of non-small cell lung cancer (NSCLC). Reflex testing for EGFR mutations, ALK rearrangements and PD-L1 would help treating oncologists to optimise treatment decisions and avoid delays in treatment.
Recorded at the 2017 meeting of the British Thoracic Oncology Group (BTOG) in Dublin, Ireland.
Get great new content delivered to your inboxSign up